AGO-OVAR16:晚期卵巢癌一线化疗后未进展者维持帕唑帕尼对比安慰剂的总生存期结果
AGO-OVAR16研究将940例新诊断晚期卵巢癌(FIGO II-IV期)患者按1:1随机分配接受帕唑帕尼800mg每日一次或安慰剂维持治疗最长24个月。最终总生存期分析时共发生494例事件,两组总生存期无差异(HR 0.960,95%CI 0.805-1.145),中位总生存期帕唑帕尼组59.1个月 vs 安慰剂组64.0个月。探索性分析显示帕唑帕尼组至首次后续抗癌治疗或死亡时间有延长趋势(HR 0.829,95%CI 0.713-0.965)。
要点
- 帕唑帕尼维持治疗延长无进展生存期,但未改善中位总生存期。
- 最终分析时帕唑帕尼组与安慰剂组总生存期无差异(HR 0.960,95%CI 0.805-1.145)。
- 探索性分析显示帕唑帕尼组至首次后续抗癌治疗或死亡时间有延长趋势(HR 0.829)。
核心结论
- 帕唑帕尼虽延长无进展生存期,但未伴随中位总生存期改善。
研究设计与样本
- AGO-OVAR16为3期研究,纳入940例组织学确诊的晚期卵巢癌(FIGO II-IV期)患者,按1:1随机分配接受帕唑帕尼800mg每日一次或安慰剂,最长24个月,直至疾病进展、毒性、撤回知情同意或死亡。
- 主要终点无进展生存期(研究者评估)已达到并既往报告,本文报告总生存期最终分析结果。
主要发现
- 第三次总生存期期中分析显示无效,导致研究关闭并进行末例患者末次访视后的最终总生存期分析。
- 最终总生存期分析时发生494例事件(占计划551例的89.7%)。
- 帕唑帕尼组与安慰剂组总生存期无差异,HR为0.960(95%CI 0.805-1.145),自随机化起中位总生存期帕唑帕尼组59.1个月 vs 安慰剂组64.0个月。
- 东亚患者中,与前三次总生存期期中分析相似,观察到有利于安慰剂的数值负向趋势(HR 1.332,95%CI 0.863-2.054)。
- 探索性分析显示帕唑帕尼组至首次后续抗癌治疗或死亡时间有延长趋势(HR 0.829,95%CI 0.713-0.965),中位估计值分别为19.0个月和14.5个月。
局限性
- 第三次总生存期期中分析显示无效,导致研究关闭。
- 总生存期最终分析时发生494例事件,占计划551例的89.7%。
- 东亚患者中观察到有利于安慰剂的数值负向趋势(HR 1.332,95%CI 0.863-2.054)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The AGO-OVAR16 study was designed to test the efficacy, safety, and tolerability of pazopanib maintenance after first-line chemotherapy in patients with newly diagnosed advanced ovarian cancer (AOC). METHODS: Nine hundred and forty patients with histologically confirmed AOC, International Federation of Gynecology and Obstetrics (FIGO) stage II-IV, were randomized in a 1:1 ratio to receive either 800 mg pazopanib once daily or placebo for up to 24 months, unless there was disease progression, toxicity, withdrawal of consent, or death. The primary endpoint (investigator-assessed progression-free survival [PFS]) was met and previously reported. The results of final analyses of overall survival (OS) are reported here. RESULTS: A third OS interim analysis showed futility and led to study closure and a final OS analysis after last patient last visit. At the time of the final OS analysis, 494 (89.7% of the planned 551) events had occurred. No difference was observed in OS between pazopanib and placebo. The hazard ratio (HR) was 0.960 (95% confidence interval [CI]: 0.805-1.145), and the median OS from randomization was 59.1 months in pazopanib and 64.0 months in placebo arms. For the East Asian patients, similar to the first three interim OS analyses, a numerical negative trend was observed favoring placebo (HR, 1.332; 95% CI: 0.863-2.054). Exploratory analyses showed a trend for a longer time to first subsequent anti-cancer therapy or death with pazopanib over placebo (HR, 0.829; 95% CI: 0.713-0.965), with a median estimate of 19.0 and 14.5 months, respectively. No new safety signals were observed. CONCLUSION: Although pazopanib prolonged PFS, this was not associated with improvement in median OS. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov: NCT00866697.
引用
- Vergote I, du Bois A, Floquet A, et al. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019. PMID: 31519320. doi:10.1016/j.ygyno.2019.08.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。